MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
-Any Adverse events-	0	27(84.4%)	32(97.0%)
	1	25(78.1%)	31(93.9%)
	2	15(46.9%)	25(75.8%)
	3	5(15.6%)	7(21.2%)
	4	(0.0%)	1(3.0%)
	5	(0.0%)	(0.0%)
BLOOD AND LYMPHATIC SYSTEM DISORDERS			
-overall-	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Leukopenia	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Neutropenia	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
CARDIAC DISORDERS			
-overall-	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Palpitations	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
EAR AND LABYRINTH DISORDERS			
-overall-	0	(0.0%)	3(9.1%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	2(6.1%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Deafness Neurosensory	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Ear Disorder	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Vertigo	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
ENDOCRINE DISORDERS			
-overall-	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Hypothyroidism	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
EYE DISORDERS			
-overall-	0	1(3.1%)	1(3.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	1(3.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Cataract	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	1(3.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Dry Eye	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Lacrimation Increased	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
GASTROINTESTINAL DISORDERS			

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
-overall-	0	14(43.8%)	24(72.7%)
	1	7(21.9%)	16(48.5%)
	2	6(18.8%)	6(18.2%)
	3	1(3.1%)	2(6.1%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Nausea	0	21(65.6%)	13(39.4%)
	1	5(15.6%)	13(39.4%)
	2	3(9.4%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Abdominal Discomfort	0	3(9.4%)	1(3.0%)
	1	1(3.1%)	1(3.0%)
	2	1(3.1%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Abdominal Distension	0	5(15.6%)	3(9.1%)
	1	1(3.1%)	2(6.1%)
	2	(0.0%)	2(6.1%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Abdominal Pain	0	11(34.4%)	6(18.2%)
	1	2(6.3%)	5(15.2%)
	2	2(6.3%)	1(3.0%)
	3	(0.0%)	1(3.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Abdominal Pain Lower	0	3(9.4%)	2(6.1%)
	1	1(3.1%)	2(6.1%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Abdominal Pain Upper	0	11(34.4%)	6(18.2%)
	1	1(3.1%)	6(18.2%)
	2	1(3.1%)	2(6.1%)
	3	(0.0%)	1(3.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Aphthous Stomatitis	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Ascites	0	1(3.1%)	(0.0%)
	1	(0.0%)	(0.0%)
	2	1(3.1%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Constipation	0	14(43.8%)	9(27.3%)
	1	3(9.4%)	9(27.3%)
	2	2(6.3%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Diarrhoea	0	10(31.3%)	5(15.2%)
	1	4(12.5%)	3(9.1%)
	2	1(3.1%)	2(6.1%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Dry Mouth	0	(0.0%)	4(12.1%)
	1	(0.0%)	4(12.1%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Duodenitis	0	(0.0%)	2(6.1%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Dyspepsia	0	2(6.3%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	1(3.1%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Dysphagia	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Flatulence	0	2(6.3%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	1(3.1%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Frequent Bowel Movements	0	2(6.3%)	1(3.0%)
	1	1(3.1%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
Gastritis	0	(0.0%)	2(6.1%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Haematochezia	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Haemorrhoids	0	(0.0%)	2(6.1%)
	1	(0.0%)	2(6.1%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Hypoaesthesia Oral	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Infrequent Bowel Movements	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Lip Swelling	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Mouth Haemorrhage	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Paraesthesia Oral	0	3(9.4%)	1(3.0%)
	1	2(6.3%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Rectal Haemorrhage	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Salivary Hypersecretion	0	(0.0%)	2(6.1%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Small Intestinal Obstruction	0	1(3.1%)	(0.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	1(3.1%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Stomatitis	0	(0.0%)	4(12.1%)
	1	(0.0%)	3(9.1%)

Image: Company of the compan	MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
Vomiting 4 (0.0%) (0.0%) Vomiting 0 10(31.3%) 7(21.2%) 1 1(3.1%) 6(18.2%) 2 (0.0%) 3(9.1%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS . . -overall- 0 12(37.5%) 13(39.4%) -0 4 (0.0%) 4(12.1%) 4(12.1%) 3 (0.0%) 4(12.1%) 4(12.1%) 4 (0.0%) 13(3.0%) 4(12.1%) 4 (0.0%) 13(0.0%) 4(12.1%) 4 (0.0%) (0.0%) 4(12.1%) 5 (0.0%) (0.0%) 4(12.1%) 6 1 10(31.3%) 7(21.2%) 7 1 10(31.3%) 7(21.2%) 8 1 10(31.3%) 7(21.2%) 9 1 1 10(3.1%) 10(0.0%) 1 0.0%) 1 <t< td=""><td></td><td>2</td><td>(0.0%)</td><td>1(3.0%)</td></t<>		2	(0.0%)	1(3.0%)
Vomiting 5 (0.0%) (0.0%) Vomiting 0 10(31.3%) 7(21.2%) 1 1(3.1%) 6(18.2%) 2 (0.0%) 39.1%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 6 0 12(37.5%) 13(39.4%) -overall- 0 12(37.5%) 13(39.4%) -overall- 1 9(28.1%) 8(24.2%) 2 3(9.4%) 4(12.1%) 3 (0.0%) 13(39.4%) 4 (0.0%) 13(39.4%) 4 (0.0%) 13(39.4%) 4 (0.0%) 13(39.4%) 4 (0.0%) 13(30.9%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 6 1(0.0%) (0.0%) 7 1(1.3%) (0.0%) 8 1(0.0%) (0.0%) 1 0(0.0%) (0.		3	(0.0%)	(0.0%)
Vomiting 0 10(31.3%) 7(21.2%) 1 1(3.1%) 6(18.2%) 2 (0.0%) 39.1%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) -overall 0 12(37.5%) 13(39.4%) -overall 1 9(28.1%) 8(24.2%) 2 3(9.4%) 4(12.1%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 6 1 10(31.3%) 7(21.2%) 7 1 10(3.1%) (0.0%) 8 0 21(65.6%) 7(21.2%) 9 1 10(31.3%) 7(21.2%) 1 10(31.3%) 7(21.2%) 1 10(31.3%) 7(21.2%) 2 1(3.1%) 2(6.1%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4		4	(0.0%)	(0.0%)
1		5	(0.0%)	(0.0%)
2	Vomiting	0	10(31.3%)	7(21.2%)
3		1	1(3.1%)	6(18.2%)
A		2	(0.0%)	3(9.1%)
S (0.0%) (0.0%) (0.0%) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS .		3	(0.0%)	(0.0%)
CENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS		4	(0.0%)	(0.0%)
-overall- -overall- 1 9(28.1%) 8(24.2%) 2 3(9.4%) 4(12.1%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Fatigue 0 21(65.6%) 7(21.2%) 1 10(31.3%) 7(21.2%) 2 1(3.1%) 2(6.1%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) Asthenia 0 (0.0%) 4(12.1%) 5 (0.0%) (0.0%) 5 (0.0%) (0.0%) Asthenia 0 (0.0%) 4(12.1%) 1 (0.0%) 2(6.1%) 2 (0.0%) 2(6.1%) 3 (0.0%) (0.0%) Chest Pain 0 1(3.1%) (0.0%) 1 (0.0%) (0.0%) 1 (0.0%) (0.0%) Chest Pain 1 (0.0%) (0.0%) 1 (0.0%) (0.0%)		5	(0.0%)	(0.0%)
1 9(28.1%) 8(24.2%) 2 3(9.4%) 4(12.1%) 3 (0.0%) (13.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 7(21.2%) 1 10(31.3%) 7(21.2%) 2 1(3.1%) 2(6.1%) 3 (0.0%) (13.0%) 4 (0.0%) (0.0%) 5 (0.0%) (13.0%) 4 (0.0%) (0.0%) 5 (0.0%) (12.1%) 6 (0.0%) (12.1%) 7 (0.0%) (12.1%) 8 (0.0%) (13.0%) 9 (0.0%) (13.0%) 1 (0.0%) (13.1%) (0.0%) 1 (0.0%) (0.0%) 1 (0.0%) (0.0%) 1 (0.0%) (0.0%) 1 (0.0%) (0.0%) 2 (13.1%) (0.0%) 3 (0.0%) (0.0%) 1 (0.0%) (0.0%) 2 (13.1%) (0.0%) 3 (0.0%) (0.0%) 1 (0.0%) (0.0%) 1 (0.0%) (0.0%) 2 (13.1%) (0.0%) 3 (0.0%) (0.0%)	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS			
2 3(9.4%) 4(12.1%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) (0.0%) 5 (0.0%)	-overall-	0	12(37.5%)	13(39.4%)
3		1	9(28.1%)	8(24.2%)
4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Fatigue 0 21(65.6%) 7(21.2%) 1 10(31.3%) 7(21.2%) 2 1(3.1%) 2(6.1%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 4 (0.0%) 2(6.1%) 2 (0.0%) 2(6.1%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Chest Pain 0 1(3.1%) (0.0%) 1 (0.0%) (0.0%) 2 1(3.1%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%)		2	3(9.4%)	4(12.1%)
Fatigue 0 21(65.6%) 7(21.2%) 1 10(31.3%) 7(21.2%) 2 1(3.1%) 2(6.1%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Asthenia 0 (0.0%) 2(6.1%) 2 (0.0%) 2(6.1%) 2 (0.0%) 2(6.1%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 4 (0.0%) (0.0%) Chest Pain 0 1(3.1%) (0.0%) 1 (0.0%) (0.0%) 2 1(3.1%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%)		3	(0.0%)	1(3.0%)
Fatigue 0 21(65.6%) 7(21.2%) 1 10(31.3%) 7(21.2%) 2 1(3.1%) 2(6.1%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Asthenia 0 (0.0%) 2(6.1%) 2 (0.0%) 2(6.1%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) Chest Pain 0 1(3.1%) (0.0%) 1 (0.0%) (0.0%) 2 1(3.1%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%)		4	(0.0%)	(0.0%)
1 10(31.3%) 7(21.2%) 2 1(3.1%) 2(6.1%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Asthenia 0 (0.0%) 4(12.1%) 1 (0.0%) 2(6.1%) 2 (0.0%) 2(6.1%) 2 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Chest Pain 0 1(3.1%) (0.0%) Chest Pain 0 1(3.1%) (0.0%) 1 (0.0%) (0.0%) 2 1(3.1%) (0.0%)		5	(0.0%)	(0.0%)
2 1(3.1%) 2(6.1%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Asthenia 0 (0.0%) 4(12.1%) 1 (0.0%) 2(6.1%) 2 (0.0%) 2(6.1%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 1 (0.0%) (0.0%) Chest Pain 0 1(3.1%) (0.0%) 1 (0.0%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%)	Fatigue	0	21(65.6%)	7(21.2%)
3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Asthenia 0 (0.0%) 4(12.1%) 1 (0.0%) 2(6.1%) 2 (0.0%) 2(6.1%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 5 (0.0%) (0.0%) Chest Pain 0 1(3.1%) (0.0%) 1 (0.0%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%)		1	10(31.3%)	7(21.2%)
4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Asthenia 0 (0.0%) 4(12.1%) 1 (0.0%) 2(6.1%) 2 (0.0%) 2(6.1%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 5 (0.0%) (0.0%) 1 (0.0%) (0.0%) 1 (0.0%) (0.0%) 2 1(3.1%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%)		2	1(3.1%)	2(6.1%)
Asthenia 5 (0.0%) (0.0%) 1 (0.0%) 2(6.1%) 2 (0.0%) 2(6.1%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 1 (0.0%) (0.0%) 2 1(3.1%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%)		3	(0.0%)	1(3.0%)
Asthenia 0 (0.0%) 4(12.1%) 1 (0.0%) 2(6.1%) 2 (0.0%) 2(6.1%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Chest Pain 0 1(3.1%) (0.0%) 1 (0.0%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%)		4	(0.0%)	(0.0%)
1 (0.0%) 2(6.1%) 2 (0.0%) 2(6.1%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Chest Pain 0 1(3.1%) (0.0%) 1 (0.0%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%)		5	(0.0%)	(0.0%)
2 (0.0%) 2(6.1%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Chest Pain 0 1(3.1%) (0.0%) 1 (0.0%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%)	Asthenia	0	(0.0%)	4(12.1%)
3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Chest Pain 0 1(3.1%) (0.0%) 1 (0.0%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%)		1	(0.0%)	2(6.1%)
4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Chest Pain 0 1(3.1%) (0.0%) 1 (0.0%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%)		2	(0.0%)	2(6.1%)
5 (0.0%) (0.0%) Chest Pain 0 1(3.1%) (0.0%) 1 (0.0%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%)		3	(0.0%)	(0.0%)
Chest Pain 0 1(3.1%) (0.0%) 1 (0.0%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%)		4	(0.0%)	(0.0%)
1 (0.0%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%)		5	(0.0%)	(0.0%)
2 1(3.1%) (0.0%) 3 (0.0%) (0.0%)	Chest Pain	0	1(3.1%)	(0.0%)
3 (0.0%) (0.0%)		1	(0.0%)	(0.0%)
		2	1(3.1%)	(0.0%)
4 (0.0%) (0.0%)		3	(0.0%)	(0.0%)
		4	(0.0%)	(0.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	5	(0.0%)	(0.0%)
Influenza Like Illness	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Mucosal Inflammation	0	3(9.4%)	1(3.0%)
	1	2(6.3%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Oedema	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Pain	0	2(6.3%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	1(3.1%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Pyrexia	0	(0.0%)	3(9.1%)
	1	(0.0%)	2(6.1%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
IMMUNE SYSTEM DISORDERS			
-overall-	0	1(3.1%)	1(3.0%)
	1	1(3.1%)	1(3.0%)

MedDRA System Organ Class			
and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Hypersensitivity	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Hypogammaglobulinaemia	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
INFECTIONS AND INFESTATIONS			
-overall-	0	9(28.1%)	10(30.3%)
	1	3(9.4%)	4(12.1%)
	2	4(12.5%)	6(18.2%)
	3	2(6.3%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Influenza	0	5(15.6%)	3(9.1%)
	1	1(3.1%)	2(6.1%)
	2	1(3.1%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Bronchitis	0	2(6.3%)	(0.0%)
	1	(0.0%)	(0.0%)
	2	2(6.3%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)

MedDRA System Organ Class	NCI CTCAE	Dlacaba	CMD 125
and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	5	(0.0%)	(0.0%)
Cystitis	0	2(6.3%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	1(3.1%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Device Related Infection	0	1(3.1%)	(0.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	1(3.1%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Gastroenteritis	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Gastroenteritis Norovirus	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Herpes Zoster	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Infection	0	1(3.1%)	(0.0%)
	1	(0.0%)	(0.0%)
	2	1(3.1%)	(0.0%)

Image: Company of the company of th	MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
Lower Respiratory Tract Infection 1		3	(0.0%)	(0.0%)
Lower Respiratory Tract Infection 0 1(3.1%) (0.0%) 1 1(3.1%) (0.0%) (0.0%) 2 (0.0%) (0.0%) (0.0%) 3 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) Nasopharyngitis 0 (0.0%) (13.0%) 2 (0.0%) (0.0%) (0.0%) 3 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) Coral Herpes 0 (0.0%) (0.0%) Coral Herpes 0 (0.0%) (0.0%) 3 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) 5 (0.0%) (0.0%) (0.0%) Pharyngitis 0 2(6.3%) (0.0%) <tr< td=""><td></td><td>4</td><td>(0.0%)</td><td>(0.0%)</td></tr<>		4	(0.0%)	(0.0%)
1		5	(0.0%)	(0.0%)
2	Lower Respiratory Tract Infection	0	1(3.1%)	(0.0%)
3		1	1(3.1%)	(0.0%)
A		2	(0.0%)	(0.0%)
Nasopharyngitis 5 (0.0%) (0.0%) 1 (0.0%) 1(3.0%) 2 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 1 (0.0%) 2(6.1%) 1 (0.0%) 1(3.0%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 6 2 (0.0%) (0.0%) 9 1 1(3.1%) (0.0%) 1 1(3.1%) (0.0%) (0.0%) 2 1(3.1%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) 5 (0.0%) (0.0%) (0.0%) 6 0.0%) (0.0%) (0.0%) 7 0.0%) (0.0%) (0.0%) 8 0.0%) (0.0%)		3	(0.0%)	(0.0%)
Nasopharyngitis 0 (0.0%) 1(3.0%) 1 (0.0%) 1(3.0%) 2 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 1 (0.0%) 1(3.0%) 2 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 2 (0.0%) (0.0%) 4 (0.0%) (0.0%) Pharyngitis 0 2(6.3%) (0.0%) Pharyngitis 0 2(6.3%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 5 (0.0%) (0.0%) 6 (0.0%) (0.0%) 7 (0.0%) (0.0%) 8 (0.0%) (0.0%) 9 (0.0%) (0.0%) 1 </td <td></td> <td>4</td> <td>(0.0%)</td> <td>(0.0%)</td>		4	(0.0%)	(0.0%)
1		5	(0.0%)	(0.0%)
2	Nasopharyngitis	0	(0.0%)	1(3.0%)
3		1	(0.0%)	1(3.0%)
4		2	(0.0%)	(0.0%)
Oral Herpes 5 (0.0%) (0.0%) 1 (0.0%) 1(3.0%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Pharyngitis 0 2(6.3%) (0.0%) 1 1(3.1%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 5 (0.0%) (0.0%) 5 (0.0%) (0.0%) 1 (0.0%) (0.0%) 5 (0.0%) (0.0%) 1 (0.0%) (0.0%) 2 (0.0%) (13.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 4 (0.0%)		3	(0.0%)	(0.0%)
Oral Herpes 0 (0.0%) 2(6.1%) 1 (0.0%) 1(3.0%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 1 1(3.1%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 5 (0.0%) (0.0%) 1 (0.0%) (0.0%) 5 (0.0%) (0.0%) 1 (0.0%) (0.0%) 2 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 6 (0.0%) (0.0%)		4	(0.0%)	(0.0%)
1 (0.0%) 1(3.0%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Pharyngitis 0 2(6.3%) (0.0%) 1 1(3.1%) (0.0%) 2 1(3.1%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 5 (0.0%) (0.0%) 5 (0.0%) 1(3.0%) 5 (0.0%) 1(3.0%) 6 (0.0%) 1(3.0%) 7 (0.0%) 1(3.0%) 7 (0.0%) 1(3.0%) 8 (0.0%) (0.0%) 9 (0.0%) 1(3.0%) 9 (0.0%) 1(3.0%) 1 (0.0%) (0.0%) 1 (0.0%) (0.0%) 1 (0.0%) (0.0%)		5	(0.0%)	(0.0%)
2	Oral Herpes	0	(0.0%)	2(6.1%)
3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Pharyngitis 0 2(6.3%) (0.0%) 1 1(3.1%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 5 (0.0%) (0.0%) Sinusitis 0 (0.0%) 1(3.0%) 1 (0.0%) (0.0%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 5 (0.0%) (0.0%) 5 (0.0%) (0.0%) 6 (0.0%) (0.0%) 7 (0.0%) (0.0%) 7 (0.0%) (0.0%) 8 (0.0%) (0.0%) 9 (0.0%) (0.0%) 9 (0.0%) (0.0%)		1	(0.0%)	1(3.0%)
4		2	(0.0%)	1(3.0%)
Pharyngitis 5 (0.0%) (0.0%) 1 1(3.1%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Sinusitis 0 (0.0%) 1(3.0%) 1 (0.0%) (0.0%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		3	(0.0%)	(0.0%)
Pharyngitis 0 2(6.3%) (0.0%) 1 1(3.1%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 1 (0.0%) (0.0%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		4	(0.0%)	(0.0%)
1 1(3.1%) (0.0%) 2 1(3.1%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Sinusitis 0 (0.0%) 1(3.0%) 1 (0.0%) (0.0%) 2 (0.0%) 1(3.0%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		5	(0.0%)	(0.0%)
2 1(3.1%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Sinusitis 0 (0.0%) 1(3.0%) 1 (0.0%) (0.0%) 2 (0.0%) 1(3.0%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)	Pharyngitis	0	2(6.3%)	(0.0%)
3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Sinusitis 0 (0.0%) 1(3.0%) 1 (0.0%) (0.0%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		1	1(3.1%)	(0.0%)
4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Sinusitis 0 (0.0%) 1(3.0%) 1 (0.0%) (0.0%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		2	1(3.1%)	(0.0%)
5 (0.0%) (0.0%) Sinusitis 0 (0.0%) 1(3.0%) 1 (0.0%) (0.0%) 1(3.0%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		3	(0.0%)	(0.0%)
Sinusitis 0 (0.0%) 1(3.0%) 1 (0.0%) (0.0%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		4	(0.0%)	(0.0%)
1 (0.0%) (0.0%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		5	(0.0%)	(0.0%)
2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)	Sinusitis	0	(0.0%)	1(3.0%)
3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		1	(0.0%)	(0.0%)
4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		2	(0.0%)	1(3.0%)
5 (0.0%) (0.0%)		3	(0.0%)	(0.0%)
		4	(0.0%)	(0.0%)
Tonsillitis 0 (0.0%) 1(3.0%)		5	(0.0%)	(0.0%)
	Tonsillitis	0	(0.0%)	1(3.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Tooth Infection	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Upper Respiratory Tract Infection	0	2(6.3%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	1(3.1%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Urinary Tract Infection	0	2(6.3%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	1(3.1%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Vaginal Infection	0	1(3.1%)	(0.0%)
	1	(0.0%)	(0.0%)
	2	1(3.1%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Viral Upper Respiratory Tract Infection	0	1(3.1%)	(0.0%)
	1	(0.0%)	(0.0%)
	2	1(3.1%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	5	(0.0%)	(0.0%)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS			
-overall-	0	1(3.1%)	5(15.2%)
	1	(0.0%)	2(6.1%)
	2	1(3.1%)	3(9.1%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Contusion	0	3(9.4%)	2(6.1%)
	1	(0.0%)	2(6.1%)
	2	1(3.1%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Procedural Pain	0	(0.0%)	3(9.1%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	2(6.1%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Thermal Burn	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Wrist Fracture	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
INVESTIGATIONS			
-overall-	0	4(12.5%)	6(18.2%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	1	2(6.3%)	3(9.1%)
	2	2(6.3%)	2(6.1%)
	3	(0.0%)	1(3.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Weight Decreased	0	6(18.8%)	5(15.2%)
	1	(0.0%)	3(9.1%)
	2	1(3.1%)	2(6.1%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Alanine Aminotransferase Increased	0	(0.0%)	2(6.1%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	1(3.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Aspartate Aminotransferase Increased	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Blood Alkaline Phosphatase Increased	0	(0.0%)	2(6.1%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Blood Pressure Increased	0	1(3.1%)	(0.0%)
	1	(0.0%)	(0.0%)
	2	1(3.1%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	5	(0.0%)	(0.0%)
Blood Urea Increased	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Gamma-Glutamyltransferase Increased	0	3(9.4%)	1(3.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	1(3.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Vitamin B12 Decreased	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
METABOLISM AND NUTRITION DISORDERS			
-overall-	0	3(9.4%)	9(27.3%)
	1	2(6.3%)	3(9.1%)
	2	(0.0%)	5(15.2%)
	3	1(3.1%)	1(3.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Decreased Appetite	0	10(31.3%)	7(21.2%)
	1	1(3.1%)	4(12.1%)
	2	(0.0%)	4(12.1%)
	3	(0.0%)	1(3.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Dehydration	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Hyperchloraemia	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Hypocalcaemia	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Hypomagnesaemia	0	3(9.4%)	2(6.1%)
	1	1(3.1%)	1(3.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Hyponatraemia	0	1(3.1%)	(0.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	1(3.1%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Type 2 Diabetes Mellitus	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS			
-overall-	0	15(46.9%)	27(81.8%)
	1	10(31.3%)	12(36.4%)
	2	5(15.6%)	14(42.4%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	1(3.0%)
	5	(0.0%)	(0.0%)
Muscle Spasms	0	33(103.1%)	21(63.6%)
	1	4(12.5%)	17(51.5%)
	2	1(3.1%)	10(30.3%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	1(3.0%)
	5	(0.0%)	(0.0%)
Arthralgia	0	11(34.4%)	5(15.2%)
	1	5(15.6%)	3(9.1%)
	2	1(3.1%)	2(6.1%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Arthritis	0	2(6.3%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	1(3.1%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Back Pain	0	8(25.0%)	5(15.2%)
	1	3(9.4%)	3(9.1%)
	2	(0.0%)	2(6.1%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Bone Pain	0	2(6.3%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	1(3.1%)	(0.0%)

3	MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
Groin Pain 5 (0.0%) 10.0%) Groin Pain 0 13.1%) (0.0%) 1 (0.0%) (0.0%) (0.0%) 2 13.1%) (0.0%) (0.0%) 3 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) Joint Stiffness 0 2 (6.3%) 13.0%) 1 13.1%) 13.0%) (0.0%) 2 (0.0%) (0.0%) (0.0%) 3 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) Muscular Weakness 0 (0.0%) (0.0%) Muscular Weakness 0 (0.0%) (0.0%) Muscular Weakness 0 (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) Muscular Weakness 0 (0.0%) (0.0%) Muscular Weakness 0 (0.0%) (0.0%)		3	(0.0%)	(0.0%)
Groin Pain 0 1(3.1%) 0.0%) 1 (0.0%) (0.0%) (0.0%) 2 1(3.1%) (0.0%) (0.0%) 3 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) Joint Siffness 0 26.3%) (13.0%) 1 1 (3.1%) (13.0%) (0.0%) 2 (0.0%) (0.0%) (0.0%) 3 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) Muscular Weakness 0 (0.0%) (13.0%) Muscular Weakness 0 (0.0%) (13.0%) 1 (0.0%) (0.0%) (0.0%) 1 (0.0%) (0.0%) (0.0%) 2 (0.0%) (0.0%) (0.0%) Muscular Weakness 0 (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%)		4	(0.0%)	(0.0%)
1		5	(0.0%)	(0.0%)
	Groin Pain	0	1(3.1%)	(0.0%)
3		1	(0.0%)	(0.0%)
Marculoskeletal Chest Pain Marculoskeletal Pain Marculoskeleta		2	1(3.1%)	(0.0%)
S (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (1.3.0%) (1.3.0%) (1.3.1%) (1.3.0%) (0.0%)		3	(0.0%)	(0.0%)
Joint Stiffness 0 2(6.3%) 1(3.0%) 1 1(3.1%) 1(3.0%) 2 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) Muscular Weakness 0 (0.0%) 1(3.0%) 1 (0.0%) 1(3.0%) (0.0%) 2 (0.0%) (0.0%) (0.0%) 3 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) Musculoskeletal Chest Pain 0 (0.0%) 1(3.0%) 4 (0.0%) 1(3.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) 4 (0.0%) (0.0%) (0.0%) Musculoskeletal Pain 0 6(18.8%) 5(15.2%) 4 (0.0%) (0.0%) (0.0%)		4	(0.0%)	(0.0%)
1 1(3.1%) 1(3.0%) (0.0		5	(0.0%)	(0.0%)
2	Joint Stiffness	0	2(6.3%)	1(3.0%)
3		1	1(3.1%)	1(3.0%)
A		2	(0.0%)	(0.0%)
Muscular Weakness 0 (0.0%) 1(3.0%) Muscular Weakness 0 (0.0%) 1(3.0%) 1 (0.0%) 1(3.0%) 2 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) Musculoskeletal Chest Pain 0 (0.0%) 1(3.0%) 1 (0.0%) 1(3.0%) 1 (0.0%) 1(3.0%) 2 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) Musculoskeletal Pain 0 (0.0%) (0.0%) 1 (1.0%) (0.0%) 4 (0.0%) (0.0%) Musculoskeletal Pain 0 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) Musculoskeletal Pain 0 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) Musculoskeletal Pain 0 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 6 (0.0%) (0.0%) 6 (0.0%) (0.0%) 6 (0.0%) (0.0%) 6 (0.0%) (0.0%) 6 (0.0%) (0.0%)		3	(0.0%)	(0.0%)
Muscular Weakness 0 (0.0%) 1(3.0%) 1 (0.0%) 1(3.0%) 2 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) Musculoskeletal Chest Pain 0 (0.0%) 1(3.0%) 1 (0.0%) 1(3.0%) 2 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) Musculoskeletal Pain 0 6(18.8%) 5(15.2%) Musculoskeletal Pain 0 6(18.8%) 5(15.2%) Musculoskeletal Pain 0 6(18.8%) 5(15.2%) 1 1(3.1%) 4(12.1%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 6 (0.0%) (0.0%) 7 (0.0%) (0.0%)		4	(0.0%)	(0.0%)
1		5	(0.0%)	(0.0%)
2	Muscular Weakness	0	(0.0%)	1(3.0%)
3		1	(0.0%)	1(3.0%)
4		2	(0.0%)	(0.0%)
Musculoskeletal Chest Pain 5 (0.0%) (0.0%) 1 (0.0%) 1(3.0%) 2 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Musculoskeletal Pain 0 6(18.8%) 5(15.2%) 1 1(3.1%) 4(12.1%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		3	(0.0%)	(0.0%)
Musculoskeletal Chest Pain 0 (0.0%) 1(3.0%) 1 (0.0%) 1(3.0%) 2 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Musculoskeletal Pain 0 6(18.8%) 5(15.2%) 1 1(3.1%) 4(12.1%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		4	(0.0%)	(0.0%)
1 (0.0%) 1(3.0%) 2 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Musculoskeletal Pain 0 6(18.8%) 5(15.2%) 1 1(3.1%) 4(12.1%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		5	(0.0%)	(0.0%)
2	Musculoskeletal Chest Pain	0	(0.0%)	1(3.0%)
3		1	(0.0%)	1(3.0%)
4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Musculoskeletal Pain 0 6(18.8%) 5(15.2%) 1 1(3.1%) 4(12.1%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		2	(0.0%)	(0.0%)
5 (0.0%) (0.0%) Musculoskeletal Pain 0 6(18.8%) 5(15.2%) 1 1(3.1%) 4(12.1%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		3	(0.0%)	(0.0%)
Musculoskeletal Pain 0 6(18.8%) 5(15.2%) 1 1(3.1%) 4(12.1%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		4	(0.0%)	(0.0%)
1 1(3.1%) 4(12.1%) 2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		5	(0.0%)	(0.0%)
2 (0.0%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)	Musculoskeletal Pain	0	6(18.8%)	5(15.2%)
3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		1	1(3.1%)	4(12.1%)
4 (0.0%) (0.0%) 5 (0.0%) (0.0%)		2	(0.0%)	1(3.0%)
5 (0.0%) (0.0%)		3	(0.0%)	(0.0%)
		4	(0.0%)	(0.0%)
Myalgia 0 4(12.5%) 2(6.1%)		5	(0.0%)	(0.0%)
	Myalgia	0	4(12.5%)	2(6.1%)

1	MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
		1	2(6.3%)	2(6.1%)
A		2	(0.0%)	(0.0%)
Neck Pain		3	(0.0%)	(0.0%)
Neck Pain 0 0 0,0% 10,0%		4	(0.0%)	(0.0%)
1		5	(0.0%)	(0.0%)
2	Neck Pain	0	(0.0%)	1(3.0%)
3		1	(0.0%)	(0.0%)
A		2	(0.0%)	1(3.0%)
Pain In Extremity 0 4(12.5%) 2(6.1%) Pain In Extremity 0 4(12.5%) 2(6.1%) 1 1(3.1%) 1(3.0%) 2 1(3.1%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 5 (0.0%) (0.0%) 5 (0.0%) (0.0%) 5 (0.0%) (0.0%) 6 (0.0%) (0.0%) 6 (0.0%) (0.0%) 7 (0.0%) (0.0%) 8 (0.0%) (0.0%) 8 (0.0%) (0.0%) 9 (0.0%) (0.0%)		3	(0.0%)	(0.0%)
Pain In Extremity 0 4(12.5%) 2(6.1%) 1 1(3.1%) 1(3.0%) 1 1(3.1%) 1(3.0%) 2 1(3.1%) 1(3.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 5 (0.0%) 1(3.0%) 5 (0.0%) 1(3.0%) 6 (0.0%) 1(3.0%) 6 (0.0%) 1(3.0%) 6 (0.0%) 1(3.0%) 6 (0.0%) 1(3.0%) 7 (0.0%) 1(3.0%) 7 (0.0%) 1(3.0%) 8 (0.0%) 1(3.0%) 8 (0.0%) 1(3.0%) 8 (0.0%) 1(3.1%) 1(3.0%) 9 (0.0%) 1 1(3.1%) 1(3.0%)		4	(0.0%)	(0.0%)
1 1(3.1%) 1(3.0%) 1(3.0%) 1 1(3.1%) 1(3.0%) 1(3.0%) 1 1(3.1%) 1(3.0%) 1 1(3.1%) 1(3.0%) 1 1(3.1%) 1 1(3.1%) 1 1(3.1%) 1 1(3.1%) 1 1(3.1%) 1 1(3.0%) 1 1 1(3.0%) 1 1 1(3.0%) 1 1 1(3.0%) 1 1 1(3.0%) 1 1 1 1(3.0%) 1 1 1 1 1 1 1 1 1		5	(0.0%)	(0.0%)
2 1(3.1%) 1(3.0%) (0.0	Pain In Extremity	0	4(12.5%)	2(6.1%)
3		1	1(3.1%)	1(3.0%)
4		2	1(3.1%)	1(3.0%)
Sensation Of Heaviness 0 (0.0%) (13.0%) (13.0%) 1 (0.0%) 1 (3.0%) 1 (0.0%) (13.0%) 2 (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (3	(0.0%)	(0.0%)
Sensation Of Heaviness 0 (0.0%) 1(3.0%) 1 (0.0%) 1(3.0%) 2 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) -overall- 0 1(3.1%) 1(3.0%) 1 1(3.1%) (0.0%) 2 (0.0%) (0.0%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) Acrochordon 0 1(3.1%) (0.0%) Acrochordon 0 1(3.1%) (0.0%) 1 1(3.1%) (0.0%) 4 (0.0%) (0.0%)		4	(0.0%)	(0.0%)
1 (0.0%) 1(3.0%) 2 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)overall- 0 1(3.1%) 1(3.0%) 1 1(3.1%) (0.0%) 2 (0.0%) (0.0%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Acrochordon 0 1(3.1%) (0.0%) 1 1(3.1%) (0.0%) 1 1(3.1%) (0.0%)		5	(0.0%)	(0.0%)
2 (0.0%) (0.0%) 3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) . -overall- 0 1(3.1%) 1(3.0%) 1 1(3.1%) (0.0%) 2 (0.0%) (0.0%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) 6 (0.0%) (0.0%) 7 (0.0%) (0.0%) 8 (0.0%) (0.0%) 9 (0.0%) (0.0%) 1 1(3.1%) (0.0%) 1 1(3.1%) (0.0%) 1 1(3.1%) (0.0%) 1 1(3.1%) (0.0%)	Sensation Of Heaviness	0	(0.0%)	1(3.0%)
3 (0.0%) (0.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) -overall- 0 1(3.1%) 1(3.0%) 1 1(3.1%) (0.0%) 2 (0.0%) (0.0%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 4 (0.0%) (0.0%) Acrochordon 0 1(3.1%) (0.0%) Acrochordon 1 1(3.1%) (0.0%) 1 1(3.1%) (0.0%)		1	(0.0%)	1(3.0%)
4 (0.0%) (0.0%) 5 (0.0%) (0.0%) NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) . -overall- 0 1(3.1%) 1(3.0%) 1 1(3.1%) (0.0%) 2 (0.0%) (0.0%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) Acrochordon 0 1(3.1%) (0.0%) 1 1(3.1%) (0.0%) 2 (0.0%) (0.0%)		2	(0.0%)	(0.0%)
5		3	(0.0%)	(0.0%)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) -overall- 0 1(3.1%) 1(3.0%) 1 1(3.1%) (0.0%) 2 (0.0%) (0.0%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Acrochordon 0 1(3.1%) (0.0%) 1 1(3.1%) (0.0%) 2 (0.0%) (0.0%)		4	(0.0%)	(0.0%)
-overall- 0 1(3.1%) 1(3.0%) 1 1(3.1%) (0.0%) 2 (0.0%) (0.0%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Acrochordon 0 1(3.1%) (0.0%) 1 1(3.1%) (0.0%) 2 (0.0%) (0.0%)		5	(0.0%)	(0.0%)
1 1(3.1%) (0.0%) 2 (0.0%) (0.0%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Acrochordon 0 1(3.1%) (0.0%) 1 1(3.1%) (0.0%) 2 (0.0%) (0.0%)	NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)			
2 (0.0%) (0.0%) 3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Acrochordon 0 1(3.1%) (0.0%) 1 1(3.1%) (0.0%) 2 (0.0%) (0.0%)	-overall-	0	1(3.1%)	1(3.0%)
3 (0.0%) 1(3.0%) 4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Acrochordon 0 1(3.1%) (0.0%) 1 1(3.1%) (0.0%) 2 (0.0%) (0.0%)		1	1(3.1%)	(0.0%)
4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Acrochordon 0 1(3.1%) (0.0%) 1 1(3.1%) (0.0%) 2 (0.0%) (0.0%)		2	(0.0%)	(0.0%)
4 (0.0%) (0.0%) 5 (0.0%) (0.0%) Acrochordon 0 1(3.1%) (0.0%) 1 1(3.1%) (0.0%) 2 (0.0%) (0.0%)		3	(0.0%)	1(3.0%)
Acrochordon 0 1(3.1%) (0.0%) 1 1(3.1%) (0.0%) 2 (0.0%) (0.0%)		4	(0.0%)	(0.0%)
1 1(3.1%) (0.0%) 2 (0.0%) (0.0%)		5	(0.0%)	(0.0%)
1 1(3.1%) (0.0%) 2 (0.0%) (0.0%)	Acrochordon	0	1(3.1%)	(0.0%)
2 (0.0%) (0.0%)		1	1(3.1%)	
		3	(0.0%)	(0.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Lung Adenocarcinoma	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	1(3.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
NERVOUS SYSTEM DISORDERS			
-overall-	0	13(40.6%)	24(72.7%)
	1	11(34.4%)	15(45.5%)
	2	2(6.3%)	9(27.3%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Dysgeusia	0	36(112.5%)	22(66.7%)
	1	10(31.3%)	20(60.6%)
	2	(0.0%)	6(18.2%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Ageusia	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Anosmia	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Dizziness	0	7(21.9%)	4(12.1%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	1	1(3.1%)	4(12.1%)
	2	1(3.1%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Dystonia	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Headache	0	6(18.8%)	4(12.1%)
	1	1(3.1%)	4(12.1%)
	2	1(3.1%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Neuropathy Peripheral	0	3(9.4%)	1(3.0%)
	1	2(6.3%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Paraesthesia	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Parosmia	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	5	(0.0%)	(0.0%)
Peripheral Sensory Neuropathy	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Syncope	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Tremor	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
PSYCHIATRIC DISORDERS			
-overall-	0	1(3.1%)	7(21.2%)
	1	1(3.1%)	5(15.2%)
	2	(0.0%)	2(6.1%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Anxiety	0	(0.0%)	3(9.1%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	2(6.1%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Depression	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Insomnia	0	3(9.4%)	2(6.1%)
	1	1(3.1%)	2(6.1%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Mood Swings	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
RENAL AND URINARY DISORDERS			
-overall-	0	3(9.4%)	1(3.0%)
	1	3(9.4%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Dysuria	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Haematuria	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
		(0.00()	(0.00()
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	5	(0.0%)	(0.0%)
Hydronephrosis	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Nephrolithiasis	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Urinary Tract Disorder	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS			
-overall-	0	1(3.1%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	1(3.1%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Pelvic Pain	0	1(3.1%)	(0.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	1(3.1%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Vulvovaginal Burning Sensation	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS			
-overall-	0	4(12.5%)	7(21.2%)
	1	4(12.5%)	4(12.1%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	2(6.1%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Cough	0	6(18.8%)	4(12.1%)
	1	2(6.3%)	4(12.1%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Dyspnoea	0	3(9.4%)	1(3.0%)
	1	2(6.3%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Emphysema	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	1(3.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Oropharyngeal Pain	0	3(9.4%)	2(6.1%)
	1	1(3.1%)	1(3.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	5	(0.0%)	(0.0%)
Pneumothorax	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Pulmonary Embolism	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	1(3.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Respiratory Tract Congestion	0	2(6.3%)	1(3.0%)
	1	1(3.1%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Rhinitis Allergic	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS			
-overall-	0	10(31.3%)	21(63.6%)
	1	8(25.0%)	10(30.3%)
	2	2(6.3%)	11(33.3%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Alopecia	0	28(87.5%)	16(48.5%)
	1	5(15.6%)	15(45.5%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	2	1(3.1%)	7(21.2%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Dry Skin	0	3(9.4%)	2(6.1%)
	1	1(3.1%)	2(6.1%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Eczema	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Erythema	0	2(6.3%)	1(3.0%)
	1	1(3.1%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Exfoliative Rash	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Hair Growth Abnormal	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
Nail Disorder	0	1(3.1%)	(0.0%)
	1	(0.0%)	(0.0%)
	2	1(3.1%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Pruritus	0	5(15.6%)	2(6.1%)
	1	3(9.4%)	1(3.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Rash	0	6(18.8%)	4(12.1%)
	1	2(6.3%)	2(6.1%)
	2	(0.0%)	2(6.1%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Rash Papular	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Skin Discolouration	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Skin Exfoliation	0	(0.0%)	1(3.0%)
	1	(0.0%)	1(3.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Skin Hyperpigmentation	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Skin Maceration	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
SURGICAL AND MEDICAL PROCEDURES			
-overall-	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Tooth Extraction	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
VASCULAR DISORDERS		, ,	<u> </u>
-overall-	0	3(9.4%)	4(12.1%)
	1	1(3.1%)	1(3.0%)
	2	2(6.3%)	2(6.1%)
	3	(0.0%)	1(3.0%)
	4	(0.0%)	(0.0%)
	"	(0.070)	(0.070)

MedDRA System Organ Class and Preferred Term	NCI-CTCAE Grade	Placebo (n=32)	CMP-135 (n=33)
	5	(0.0%)	(0.0%)
Hot Flush	0	3(9.4%)	2(6.1%)
	1	(0.0%)	1(3.0%)
	2	1(3.1%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Deep Vein Thrombosis	0	(0.0%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	1(3.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Flushing	0	1(3.1%)	(0.0%)
	1	1(3.1%)	(0.0%)
	2	(0.0%)	(0.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)
Hypertension	0	2(6.3%)	1(3.0%)
	1	(0.0%)	(0.0%)
	2	1(3.1%)	1(3.0%)
	3	(0.0%)	(0.0%)
	4	(0.0%)	(0.0%)
	5	(0.0%)	(0.0%)